Pricing Debate: GAO Report On Rx Profits Offers Ammunition To Both Sides
Executive Summary
Sen. Sanders and Rep. Cummings requested the study, which notes industry's healthy margins and offers concerns about mergers – but emphasizes the increasing cost of R&D.
You may also be interested in...
An Image To Maintain: GAO Profit Picture Of Drug Industry Is Good To Store Away For Future Debates
Big pharma has been highly successful at changing the debate from the level of drug company profitability to who shares what part of dollars generated by drug sales, but there are still lingering efforts to define and describe overall drug industry profitability and put it in the overall context of the broader economy. These efforts are backburner for now but will come back at some point in the future. Some of the portrayals are friendlier to pharma than others.
Drug Pricing: US House, Senate, Taking Bicameral Go-Slow Approach
Energy & Commerce Health Subcommittee hearing on drug pricing and the supply chain begins information gathering process, leadership says. Subcommittee Chair Burgess urges stakeholders to seek consensus on market-based solutions – or else.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.